Research Summary

I am the Ada Distinguished Professor in Thoracic Oncology and Nan T. McEvoy Distinguished Professor of Thoracic Surgical Oncology at the University of California, San Francisco (UCSF). I am also Chief of General Thoracic Surgery, Program Leader of the Thoracic Oncology Program (TOP), and Director of the Thoracic Oncology Laboratory at UCSF. I oversee a thriving bench-to-bedside program at the UCSF Helen Diller Comprehensive Cancer, comprised of thoracic surgeons, thoracic oncologists, pulmonologists, radiation oncologists, and an array of other specialists.

The Thoracic Oncology lab utilizes state-of-the-art technology such as as next-generation sequencing (NGS), synthetic chemistry, and 3D-computer simulation for assessing drug efficacy. The TOP currently offers patients a broad menu of clinical trials, testing the most promising molecularly targeted agents. In 2005, I was awarded an NIH R01 grant to investigate the role of Wnt signaling in mesothelioma, and was awarded another R01 grant in 2008 to study the role of inflammation in lung carcinogenesis. The Thoracic Oncology lab has several areas of focus including molecular therapeutics, molecular diagnostics, systems biology, systems genetics, and bench-to-bedside drug discovery. The Thoracic Oncology Lab houses one of the largest thoracic tissue bank repositories in the US, with specimens for more than 1,300 patients including fresh/frozen matched tissue (tumor, normal, serum, pbmc) for lung cancer, mesothelioma, and other cancers.

I have been a pioneer in the field of molecular diagnostics, as part of a team that developed a multi-gene diagnostic assay identifying patients at risk for recurrence of early-stage non-small-cell lung cancer. I am also a co-investigator on several other grants as part of collaborations with lead PIs in other labs: (1) Development of new immunotherapy-based drugs for the treatment of lung cancer by isolating resident immune cells in lung tumor tissue to assess the adaptive immune response; (2) Investigation of the mechanism of the KMD5A protein in rendering NSCLC resistant to EGFR TKI therapy; and (3) Investigation of the role of genetic variation in TGF-beta overactivation in COPD.

Research Funding

  • May 1, 2008 - March 31, 2014 - Inflammation and Lung Carcinogenesis, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA132566
  • March 1, 2005 - February 28, 2010 - The Wnt Pathway in Malignant Mesothelioma, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA093708
  • May 1, 2008 - March 31, 2014 - Inflammation and Lung Carcinogenesis, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA132566
  • March 1, 2005 - February 28, 2010 - The Wnt Pathway in Malignant Mesothelioma, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA093708

Education

Yale College, BA, 1975-79, American Literature
Albany Medical Col. of Union U, MD, 1979-84
Naval Hospital, Intern, 1984-85, Surgery
Tufts University, Resident, 1985-86, Surgery
National Cancer Institute, National Institutes of Health, Fellow, 1986-89, Surgical Oncology
Tufts University, 1989-91, Surgery
Brigham & Women's Hospital, Fellow, 1992-92, Lung Transplantation
Cornell University Medical Center, Fellow, 1991-93, Surgery

Honors & Awards

  • Surgical Resident Teaching Award, University of California, San Francisco, 2001
  • Surgical Resident Teaching Award, University of California, San Francisco, 1999

Selected Publications

  1. Yang YW, Phillips JJ, Jablons DM, Lemjabbar-Alaoui H Development of novel monoclonal antibodies and immunoassays for sensitive and specific detection of SULF1 endosulfatase.  View on PubMed
  2. Yang YW, Marrufo A, Chase J, Woodard GA, Jablons DM, Lemjabbar-Alaoui H Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma.  View on PubMed
  3. Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.  View on PubMed
  4. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.  View on PubMed
  5. Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.  View on PubMed
  6. Hsu PC, Yang CT, Jablons DM, You L The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).  View on PubMed
  7. Woodard GA, Jablons DM Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.  View on PubMed
  8. Haro GJ, Sheu B, Marcus SG, Sarin A, Campbell L, Jablons DM, Kratz JR Perioperative Lung Resection Outcomes After Implementation of a Multidisciplinary, Evidence-based Thoracic ERAS Program.  View on PubMed
  9. Miao J, Kyoyama H, Liu L, Chan G, Wang Y, Urisman A, Yang YL, Liu S, Xu Z, Bin H, Li H, Jablons DM, You L Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.  View on PubMed
  10. Jiang L, Tolani B, Yeh CC, Fan Y, Reza JA, Horvai AE, Xia E, Kratz JR, Jablons DM, Mann MJ Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma.  View on PubMed
  11. Woodard GA, Lee H, Fels Elliott DR, Jones KD, Wong J, Jablons DM, Ihnken K Case report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypass.  View on PubMed
  12. Hsu PC, Jablons DM, Yang CT, You L Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).  View on PubMed
  13. Agnew C, Liu L, Liu S, Xu W, You L, Yeung W, Kannan N, Jablons D, Jura N The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region.  View on PubMed
  14. Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.  View on PubMed
  15. Hsu PC, Tian B, Yang YL, Wang YC, Liu S, Urisman A, Yang CT, Xu Z, Jablons DM, You L Cucurbitacin E inhibits the Yes-associated protein signaling pathway and suppresses brain metastasis of human non-small cell lung cancer in a murine model.  View on PubMed
  16. Hung MS, Chen YC, Lin P, Li YC, Hsu CC, Lung JH, You L, Xu Z, Mao JH, Jablons DM, Yang CT Cul4A Modulates Invasion and Metastasis of Lung Cancer Through Regulation of ANXA10.  View on PubMed
  17. Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.  View on PubMed
  18. Lancaster EM, Jablons D, Kratz JR Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.  View on PubMed
  19. Hsu PC, Yang CT, Jablons DM, You L The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.  View on PubMed
  20. Haro GJ, Seeley EJ, Jablons DM, Kratz JR Central Airway Obstruction Due to Tracheal Glomus Tumor.  View on PubMed

Go to UCSF Profiles, powered by CTSI